Study guide
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up
Key Takeaways Explain This Topic AI
The patient care process is a cyclical five-step framework — collect, assess, plan, implement, and monitor and follow up — and the cycle is incomplete without a scheduled follow-up date.
Every drug therapy problem falls into one of four categories: indication, effectiveness, safety, or adherence.
A best possible medication history is built from at least two independent sources, one of which is the patient or caregiver.
Therapeutic goals must be specific, measurable, and time-bound, naming the parameter, the target, and the date it will be reassessed.
SOAP documentation records subjective and objective findings, the pharmacist's assessment, and the plan, and it is the legal record of the clinical decision.
Last updated: August 2026
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up
Exam Focus: The PEBC blueprint names "patient care process (assessment/intervention/monitoring/follow up/documentation)" as its own subcategory of Pharmacy Practice. Many Evaluating Examination items are really process questions in clinical clothing: the correct answer is the step the pharmacist has not yet completed.
The Five-Step Cycle
Canadian pharmacy practice uses a cyclical patient care process. It is a cycle, not a checklist, because the outcome of one round feeds the next.
Step What it involves
Collect Demographics, medical and medication history, allergies, laboratory data, social and cultural context, goals and preferences
Assess Interpret the information, evaluate each therapy for indication, effectiveness, safety, and adherence, and identify drug therapy problems
Plan Set measurable goals, select therapy with the patient, define monitoring parameters, and set a follow-up date
Implement Initiate, modify, or discontinue therapy within scope; educate; refer or coordinate with other providers
Monitor and follow up Reassess against the defined parameters and adjust; document the outcome
The step most often skipped, and the one examination items most often target, is the final one. A recommendation without a defined monitoring parameter and a date is an incomplete intervention.
Collecting: The Best Possible Medication History
A best possible medication history (BPMH) is a systematic, verified list of everything the patient actually takes — not what the profile says was dispensed.
Requirements:
Use at least two sources , one of which must be the patient or caregiver. Other sources include the community dispensing record, a provincial drug information system, inspection of the vials the patient brought, the referring physician's list, and the previous discharge summary.
Capture all categories: prescriptions, non-prescription products, natural health products, vitamins, inhalers, eye drops, topicals, patches, injectables, samples, and products borrowed from family.
Record drug, dose, route, frequency, indication, duration, and actual use — including doses skipped, halved, or taken on demand.
Use open-ended and normalising questions. "Many people miss doses; how many times in the last week did you miss the metformin?" gathers far more accurate information than "Are you taking your medications?"
Discrepancies found between the BPMH and the active orders are the raw material of medication reconciliation , covered in the expanded-scope section.
Assessing: Classifying Drug Therapy Problems
A drug therapy problem (DTP) is any undesirable event involving drug therapy that interferes with a desired outcome. Every DTP fits one of four categories:
Category Problem types Example
Indication Unnecessary therapy; needs additional therapy A proton pump inhibitor continued four years after the reason ended; a post-myocardial-infarction patient with no statin
Effectiveness Ineffective drug; dose too low An antibiotic that does not cover the likely organism; levothyroxine at a dose leaving thyroid-stimulating hormone raised
Safety Adverse drug reaction; dose too high Dry cough on an ACE inhibitor; gabapentin at a full dose in stage G4 kidney disease
Adherence Patient cannot or does not take the drug as intended An inhaler the patient cannot actuate; a drug the patient cannot afford
State the problem in a disciplined form: the drug, the problem, and the clinical consequence, plus the cause. "Amlodipine is causing ankle edema, which has led the patient to stop taking it, and the blood pressure is now uncontrolled" is assessable. "Possible side effect" is not.
Prioritise by risk of harm. An interaction that could cause bleeding or serotonin syndrome outranks an inconvenient dosing schedule, and an untreated urgent indication outranks both.
Planning: Goals, Alternatives, and Monitoring
Therapeutic goals must be specific, measurable, and time-bound, and they must be agreed with the patient. "Improve blood pressure" is not a goal. "Reduce home systolic blood pressure below 135 mmHg within eight weeks without orthostatic symptoms" is.
Select therapy by considering, in order: the patient's goals and values, efficacy for this indication, safety in this patient's comorbidities and organ function, interactions, ease of use, and cost and coverage. The last of these is a genuine clinical variable — a therapy the patient cannot afford has an effectiveness of zero.
Define monitoring parameters as pairs of efficacy and safety measures with a frequency:
Therapy Efficacy parameter Safety parameter
ACE inhibitor for heart failure Symptoms, weight, blood pressure Potassium and creatinine 1 to 2 weeks after each change
Levothyroxine Symptoms, thyroid-stimulating hormone at 6 to 8 weeks Palpitations, atrial fibrillation, bone density with over-replacement
- Warfarin International normalized ratio in target range Bleeding signs, hemoglobin
- Methotrexate weekly Joint counts, function Complete blood count, liver enzymes, creatinine
- Implementing and Documenting
Implementation includes what the pharmacist does directly and what is handed off. Within an expanded scope a pharmacist may adapt, renew, or initiate therapy under provincial authority; outside it, the intervention is a clear, documented, actionable recommendation to the prescriber.
Document in SOAP format:
S — Subjective: what the patient reports (symptoms, adherence, preferences).
O — Objective: measurable data (vital signs, laboratory results, dispensing history, weights).
A — Assessment: the pharmacist's clinical interpretation and the identified drug therapy problems.
P — Plan: what was done or recommended, the monitoring parameters, patient education given, and the follow-up date.
Documentation is a professional and legal obligation. It transfers care safely, evidences the standard of practice met, and is the record examined if care is later questioned. Record the rationale for a decision, not only the decision, and record recommendations that were declined along with the reason.
Monitoring and Follow-Up
Set the follow-up interval from the pharmacology, not from convenience: 1 to 2 weeks after starting an ACE inhibitor for renal function and potassium, 6 to 8 weeks after a levothyroxine change for thyroid-stimulating hormone, 4 to 6 weeks after starting a statin for tolerability and lipids, and 1 to 2 weeks after an antidepressant change for early activation and suicidality risk in young adults.
At follow-up, close the loop explicitly: was the goal met, was the therapy tolerated, did any new drug therapy problem appear, and does the plan change? Then document and set the next review.